Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAFV599Ins)

被引:68
作者
Carta, C
Moretti, S
Passeri, L
Barbi, F
Avenia, N
Cavaliere, A
Monacelli, M
Macchiarulo, A
Santeusanio, F
Tartaglia, M
Puxeddu, E
机构
[1] Univ Perugia, Dipartimento Med Interna, Sez MISEM, I-06126 Perugia, Italy
[2] Ist Super Sanita, Dipartimento Biol Cellulare & Neurosci, I-00161 Rome, Italy
[3] Univ Perugia, Ctr Riferimento Reg Endocrinochirurg, I-06126 Perugia, Italy
[4] Univ Perugia, Ist Anat Patol, I-06126 Perugia, Italy
[5] Univ Perugia, Dipartimento Chim & Tecnol Farm, I-06126 Perugia, Italy
关键词
D O I
10.1111/j.1365-2265.2005.02401.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The genes RET and RAS, and more recently BRAF, have been shown to be frequently mutated in human papillary thyroid carcinomas (PTC). The aim of this study was to genotype for these mutations a cohort of thyroid tumours collected at our institutions. Design and patients Thyroid tumours removed from 51 subjects were analysed, including 43 PTC and 8 non-PTC tumours [3 follicular adenomas (FA), 4 follicular carcinomas (FTC) and 1 anaplastic carcinoma (AC)]. Measurements RET/PTC1 and RET/PTC3 expression was evaluated by reverse transcriptase-polymerase chain reaction, whereas screening of BRAF (exon 15) and RAS (HRAS, KRAS2 and NRAS) mutations were performed, respectively, by single strand conformation polymorphism and denaturing high-pressure liquid chromatography. Results RET/PTC expressions was positive in 5/43 (11.6%) PTC and in none of the non-PTC tumour. Similarly, BRAF mutations were positive only in PTC, but with a higher prevalence (24/43 positives, 55.8%). All but one BRAF mutation resulted in the prototypic substitution of valine 600 with a glutamic acid. In one case, a somatic in-frame insertion of three bases at codon 599 resulted in the insertion of an additional valine. RET/PTC expression and BRAF mutations were mutually exclusive. Screening of the RAS gene allowed identification of oncogenic mutations in 1/3 (33.3%) FA and 3/4 (75%) FTC. None of the PTCs was positive for RAS. Conclusions These data indicate that BRAF mutations are the most frequent genetic event in PTC and that RAS mutations, besides being a genetic hallmark of follicular tumours, are rare or completely absent in PTC from our area. Together, BRAF mutations and rarer RET rearrangements accounted for a genetic event in two-thirds of PTCs. This study showed a novel and presumably oncogenic mutation of BRAF, which is BRAF(V599Ins).
引用
收藏
页码:105 / 109
页数:5
相关论文
共 26 条
[1]   Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer [J].
Ciampi, R ;
Knauf, JA ;
Kerler, R ;
Gandhi, M ;
Zhu, ZW ;
Nikiforova, MN ;
Rabes, HM ;
Fagin, JA ;
Nikiforov, YE .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (01) :94-101
[2]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[3]   Opinion - Switching on kinases: oncogenic activation of BRAF and the PDGFR family [J].
Dibb, NJ ;
Dilworth, SM ;
Mol, CD .
NATURE REVIEWS CANCER, 2004, 4 (09) :718-727
[4]  
Figge J, 2000, THYROID CANCER, P57
[5]   Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer [J].
Frattini, M ;
Ferrario, C ;
Bressan, P ;
Balestra, D ;
De Cecco, L ;
Mondellini, P ;
Bongarzone, I ;
Collini, P ;
Gariboldi, M ;
Pilotti, S ;
Pierotti, MA ;
Greco, A .
ONCOGENE, 2004, 23 (44) :7436-7440
[6]   BRAF mutations in an Italian cohort of thyroid cancers [J].
Fugazzola, L ;
Mannavola, D ;
Cirello, V ;
Vannucchi, G ;
Muzza, M ;
Vicentini, L ;
Beck-Peccoz, P .
CLINICAL ENDOCRINOLOGY, 2004, 61 (02) :239-243
[7]   BRAF mutations in papillary carcinomas of the thyroid [J].
Fukushima, T ;
Suzuki, S ;
Mashiko, M ;
Ohtake, T ;
Endo, Y ;
Takebayashi, Y ;
Sekikawa, K ;
Hagiwara, K ;
Takenoshita, S .
ONCOGENE, 2003, 22 (41) :6455-6457
[8]   A NEW ONCOGENE IN HUMAN THYROID PAPILLARY CARCINOMAS AND THEIR LYMPH-NODAL METASTASES [J].
FUSCO, A ;
GRIECO, M ;
SANTORO, M ;
BERLINGIERI, MT ;
PILOTTI, S ;
PIEROTTI, MA ;
DELLAPORTA, G ;
VECCHIO, G .
NATURE, 1987, 328 (6126) :170-172
[9]  
Kimura ET, 2003, CANCER RES, V63, P1454
[10]   Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas [J].
Kumagai, A ;
Namba, H ;
Saenko, VA ;
Ashizawa, K ;
Ohtsuru, A ;
Ito, M ;
Ishikawa, N ;
Sugino, K ;
Ito, K ;
Jeremiah, S ;
Thomas, GA ;
Bogdanova, TI ;
Tronko, MD ;
Nagayasu, T ;
Shibata, Y ;
Yamashita, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (09) :4280-4284